As part of the Englander Institute for Precision Medicine, we have an active program focused on developing patient derived tumor organoids. Organoids are 3D cellular models grown from the cancerous tissue biopsied from EIPM patients. With these models, we are able to extend our personalized medicine program to include high throughput and targeted drug screening which can be validated through genomic sequencing. Our mission is to utilize these models to predict resistance and/or direct the next line of therapy for the patient. The Tumor Organoid Platform has established a ‘living biobank’ of 62 patient tumor organoids comprising 11 different types of tumor. We are using these models to test new cancer drugs as a first step toward tailored clinical trials, as well as, further current and ongoing clinical trial research within the institution.